
ZSAN
Healthcare · Biotechnology · $2.7M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2022
EPS trend, 90 days to now · +66.7% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 13, 2022 | After the close | -1.75 | -1.76 | -0.6% |
| Mar 17, 2022 | After the close | -1.57 | -2.10 | -33.8% |
| Nov 10, 2021 | After the close | -0.08 | -0.07 | +8.7% |
| Aug 10, 2021 | After the close | -0.08 | -0.07 | +7.3% |
| May 12, 2021 | After the close | -0.08 | -0.08 | 0.0% |
| Mar 11, 2021 | After the close | -0.09 | -0.08 | +11.1% |
| Nov 13, 2020 | After the close | -0.10 | -0.11 | -13.8% |
| Aug 6, 2020 | After the close | -0.14 | -0.14 | 0.0% |
| May 14, 2020 | After the close | -0.25 | -0.24 | +5.3% |
| Mar 13, 2020 | Before the open | -0.47 | -0.45 | +5.3% |
| Nov 14, 2019 | After the close | -0.58 | -0.55 | +5.7% |
| Aug 14, 2019 | After the close | -0.56 | -0.55 | +2.4% |
| May 14, 2019 | After the close | -0.78 | -0.79 |
Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont,…
| -1.3% |
| Mar 14, 2019 | After the close | -0.69 | -0.85 | -23.2% |
| Nov 14, 2018 | After the close | -0.70 | -0.68 | +2.9% |
| Aug 9, 2018 | After the close | -0.89 | -0.75 | +15.7% |
| Apr 30, 2018 | After the close | -5.40 | -4.16 | +23.0% |
| Mar 12, 2018 | After the close | -4.80 | -3.80 | +20.8% |